Literature DB >> 19305157

Diversity of DNA damage response of astrocytes and glioblastoma cell lines with various p53 status to treatment with etoposide and temozolomide.

Yuichi Sato1, Akira Kurose, Akira Ogawa, Kuniaki Ogasawara, Frank Traganos, Zbigniew Darzynkiewicz, Takashi Sawai.   

Abstract

Phosphorylation of histone H2AX is a sensitive marker of DNA damage, particularly of DNA double strand breaks. Using multiparameter cytometry we explored effects of etoposide and temozolomide (TMZ) on three glioblastoma cell lines with different p53 status (A172, T98G, YKG-1) and on normal human astrocytes (NHA) correlating the drug-induced phosphorylated H2AX (gammaH2AX) with cell cycle phase and induction of apoptosis. Etoposide induced gammaH2AX in all phases of the cell cycle in all three glioblastoma lines and led to an arrest of T98G and YKG-1 cells in S and G(2)/M. NHA cells were arrested in G(1) with no evidence of gammaH2AX induction. A172 responded by rise in gammaH2AX throughout all phases of the cycle, arrest at the late S- to G(2)/M-phase, and appearance of senescence features: induction of p53, p21(WAF1/CIP1), p16(INK4A) and beta-galactosidase, accompanied by morphological changes typical of senescence. T98G cells showed the presence of gammaH2AX in S phase with no evidence of cell cycle arrest. A modest degree of arrest in G(1) was seen in YKG-1 cells with no rise in gammaH2AX. While frequency of apoptotic cells in all four TMZ-treated cell cultures was relatively low it is conceivable that the cells with extensive DNA damage were reproductively dead. The data show that neither the status of p53 (wild-type vs. mutated, or inhibited by pifithrin-alpha) nor the expression of O(6)-methylguanine-DNA methyltransferase significantly affected the cell response to TMZ. Because of diversity in response to TMZ between individual glioblastoma lines our data suggest that with better understanding of the mechanisms, the treatment may have to be customized to individual patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19305157      PMCID: PMC3855308          DOI: 10.4161/cbt.8.5.7740

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  44 in total

1.  A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription.

Authors:  Bong-Gun Ju; Victoria V Lunyak; Valentina Perissi; Ivan Garcia-Bassets; David W Rose; Christopher K Glass; Michael G Rosenfeld
Journal:  Science       Date:  2006-06-23       Impact factor: 47.728

2.  An accelerated senescence response to radiation in wild-type p53 glioblastoma multiforme cells.

Authors:  Quincy A Quick; David A Gewirtz
Journal:  J Neurosurg       Date:  2006-07       Impact factor: 5.115

3.  Assessment of ATM phosphorylation on Ser-1981 induced by DNA topoisomerase I and II inhibitors in relation to Ser-139-histone H2AX phosphorylation, cell cycle phase, and apoptosis.

Authors:  Akira Kurose; Toshiki Tanaka; Xuan Huang; H Dorota Halicka; Frank Traganos; Wei Dai; Zbigniew Darzynkiewicz
Journal:  Cytometry A       Date:  2005-11       Impact factor: 4.355

4.  IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide.

Authors:  Atsushi Natsume; Dai Ishii; Toshihiko Wakabayashi; Takaya Tsuno; Hisashi Hatano; Masaaki Mizuno; Jun Yoshida
Journal:  Cancer Res       Date:  2005-09-01       Impact factor: 12.701

Review 5.  Cytometric assessment of DNA damage in relation to cell cycle phase and apoptosis.

Authors:  Xuan Huang; H Dorota Halicka; Frank Traganos; Toshiki Tanaka; Akira Kurose; Zbigniew Darzynkiewicz
Journal:  Cell Prolif       Date:  2005-08       Impact factor: 6.831

6.  ATM activation and histone H2AX phosphorylation as indicators of DNA damage by DNA topoisomerase I inhibitor topotecan and during apoptosis.

Authors:  T Tanaka; A Kurose; X Huang; W Dai; Z Darzynkiewicz
Journal:  Cell Prolif       Date:  2006-02       Impact factor: 6.831

7.  O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.

Authors:  Mirjam Hermisson; Andrea Klumpp; Wolfgang Wick; Jörg Wischhusen; Georg Nagel; Wynand Roos; Bernd Kaina; Michael Weller
Journal:  J Neurochem       Date:  2006-01-09       Impact factor: 5.372

8.  O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort.

Authors:  Ian F Pollack; Ronald L Hamilton; Robert W Sobol; Judith Burnham; Allan J Yates; Emiko J Holmes; Tianni Zhou; Jonathan L Finlay
Journal:  J Clin Oncol       Date:  2006-07-20       Impact factor: 44.544

9.  A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy.

Authors:  Chris Hunter; Raffaella Smith; Daniel P Cahill; Philip Stephens; Claire Stevens; Jon Teague; Chris Greenman; Sarah Edkins; Graham Bignell; Helen Davies; Sarah O'Meara; Adrian Parker; Tim Avis; Syd Barthorpe; Lisa Brackenbury; Gemma Buck; Adam Butler; Jody Clements; Jennifer Cole; Ed Dicks; Simon Forbes; Matthew Gorton; Kristian Gray; Kelly Halliday; Rachel Harrison; Katy Hills; Jonathon Hinton; Andy Jenkinson; David Jones; Vivienne Kosmidou; Ross Laman; Richard Lugg; Andrew Menzies; Janet Perry; Robert Petty; Keiran Raine; David Richardson; Rebecca Shepherd; Alexandra Small; Helen Solomon; Calli Tofts; Jennifer Varian; Sofie West; Sara Widaa; Andy Yates; Douglas F Easton; Gregory Riggins; Jennifer E Roy; Kymberly K Levine; Wolf Mueller; Tracy T Batchelor; David N Louis; Michael R Stratton; P Andrew Futreal; Richard Wooster
Journal:  Cancer Res       Date:  2006-04-15       Impact factor: 12.701

10.  Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas.

Authors:  Marta Brell; Avelina Tortosa; Eugenia Verger; Juan Miguel Gil; Nuria Viñolas; Salvador Villá; Juan José Acebes; Lluis Caral; Teresa Pujol; Isidro Ferrer; Teresa Ribalta; Francesc Graus
Journal:  Clin Cancer Res       Date:  2005-07-15       Impact factor: 12.531

View more
  13 in total

1.  Effects of temozolomide (TMZ) on the expression and interaction of heat shock proteins (HSPs) and DNA repair proteins in human malignant glioma cells.

Authors:  Gisela Natalia Castro; Niubys Cayado-Gutiérrez; Felipe Carlos Martín Zoppino; Mariel Andrea Fanelli; Fernando Darío Cuello-Carrión; Mayra Sottile; Silvina Beatriz Nadin; Daniel Ramón Ciocca
Journal:  Cell Stress Chaperones       Date:  2014-08-26       Impact factor: 3.667

2.  Cancer Cells Employ Nuclear Caspase-8 to Overcome the p53-Dependent G2/M Checkpoint through Cleavage of USP28.

Authors:  Ines Müller; Elwira Strozyk; Sebastian Schindler; Stefan Beissert; Htoo Zarni Oo; Thomas Sauter; Philippe Lucarelli; Sebastian Raeth; Angelika Hausser; Nader Al Nakouzi; Ladan Fazli; Martin E Gleave; He Liu; Hans-Uwe Simon; Henning Walczak; Douglas R Green; Jiri Bartek; Mads Daugaard; Dagmar Kulms
Journal:  Mol Cell       Date:  2020-01-22       Impact factor: 17.970

3.  Concomitant treatment with pertussis toxin plus temozolomide increases the survival of rats bearing intracerebral RG2 glioma.

Authors:  Roxana Magaña-Maldonado; Karen Manoutcharian; Norma Y Hernández-Pedro; Edgar Rangel-López; Verónica Pérez-De la Cruz; César Rodríguez-Balderas; Julio Sotelo; Benjamín Pineda
Journal:  J Cancer Res Clin Oncol       Date:  2013-12-14       Impact factor: 4.553

4.  Methoxyamine sensitizes the resistant glioblastoma T98G cell line to the alkylating agent temozolomide.

Authors:  Ana P Montaldi; Elza T Sakamoto-Hojo
Journal:  Clin Exp Med       Date:  2012-07-25       Impact factor: 3.984

5.  Gastrin-Releasing Peptide Receptor Knockdown Induces Senescence in Glioblastoma Cells.

Authors:  Pâmela Rossi Menegotto; Patrícia Luciana da Costa Lopez; Bárbara Kunzler Souza; Caroline Brunetto de Farias; Eduardo Cremonese Filippi-Chiela; Igor Araújo Vieira; Gilberto Schwartsmann; Guido Lenz; Rafael Roesler
Journal:  Mol Neurobiol       Date:  2016-01-16       Impact factor: 5.590

6.  CDC20 regulates sensitivity to chemotherapy and radiation in glioblastoma stem cells.

Authors:  Diane D Mao; Ryan T Cleary; Amit Gujar; Tatenda Mahlokozera; Albert H Kim
Journal:  PLoS One       Date:  2022-06-23       Impact factor: 3.752

7.  Ependymoma stem cells are highly sensitive to temozolomide in vitro and in orthotopic models.

Authors:  Daniela Meco; Tiziana Servidei; Giuseppe Lamorte; Elena Binda; Vincenzo Arena; Riccardo Riccardi
Journal:  Neuro Oncol       Date:  2014-02-12       Impact factor: 12.300

8.  Glioblastoma multiforme-derived extracellular vesicles drive normal astrocytes towards a tumour-enhancing phenotype.

Authors:  Soliman Oushy; Justin E Hellwinkel; Mary Wang; Ger J Nguyen; Dicle Gunaydin; Tessa A Harland; Thomas J Anchordoquy; Michael W Graner
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-01-05       Impact factor: 6.237

9.  DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence.

Authors:  Olga V Leontieva; Mikhail V Blagosklonny
Journal:  Aging (Albany NY)       Date:  2010-12       Impact factor: 5.682

Review 10.  Chemotherapeutic Drugs: DNA Damage and Repair in Glioblastoma.

Authors:  Laura Annovazzi; Marta Mellai; Davide Schiffer
Journal:  Cancers (Basel)       Date:  2017-05-26       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.